Angelini Pharma has agreed to acquire biopharmaceutical company Catalyst Pharmaceuticals for $4.1 billion, or $31.50 per share. The deal was unanimously approved by both boards. Catalyst also resolved patent litigation related to its rare disease drug Firdapse.

Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at approximately $4.1 billion (€3.5 billion). The acquisition marks Angelini Pharma's entry into the U.S. market and strengthens its focus on brain health and rare diseases. The deal is expected to close in Q3 2026, subject to stockholder approval and regulatory clearances. Catalyst has also resolved patent litigation regarding its FIRDAPSE product.

Catalyst Pharmaceuticals and licensor SERB S.A. have settled patent litigation with Hetero Labs regarding generic FIRDAPSE (amifampridine). Under the settlement, Hetero will not market its generic version in the U.S. before January 2035 if approved by the FDA. This resolves all pending FIRDAPSE patent litigation for Catalyst, following similar settlements with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited.

Catalyst Pharmaceuticals (CPRX) trades at a 20-33% discount to pharma peers with a 7.5% free cash flow yield. The company's valuation is fairly valued to slightly undervalued at $24.50, with probability-weighted fair value around $29. The key binary catalyst is the Hetero litigation outcome expected in 2026—a win could push fair value to $28-32 with mid-teens returns through 2030, while a loss would drop it to $16-20 due to loss of FIRDAPSE patent exclusivity. Insider selling and mixed institutional positioning suggest the market has already priced in execution risks and patent cliff concerns.

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, exercised and sold 10,983 shares for approximately $256,200 on November 26, 2025, reducing his direct holdings by roughly 74%. The sale occurred following the company's strong Q3 results with revenues up 17.4% year-over-year and raised full-year guidance. While exercise-and-sell transactions are common for stock compensation management, the magnitude of this stake reduction warrants investor attention despite the company's positive operational momentum.

Long-term study of AGAMREE in Duchenne muscular dystrophy patients reveals comparable effectiveness to standard corticosteroids, with significantly lower rates of vertebral fractures and better growth maintenance over five years.

Santhera Pharmaceuticals reported positive long-term data for AGAMREE, showing comparable effectiveness to standard corticosteroids in treating Duchenne Muscular Dystrophy, with improved safety profile and reduced side effects like growth suppression and vertebral fractures.

Catalyst Pharmaceuticals and SERB S.A. reached a settlement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE, allowing Lupin to market a generic version starting February 2035, with ongoing litigation against Hetero still pending.

Santhera Pharmaceuticals will provide an update on the commercial progress of its drug AGAMREE for the treatment of Duchenne Muscular Dystrophy, as well as outline its strategic plans for further market expansion and diversification of its rare disease portfolio.

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 3 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.43, along with a high estimate of $34.00 and a low estimate of $23.00. Marking an increase of 7.98%, the current average surpasses the previous average price target of $26.33. Analyzing Analyst Ratings: A Detailed Breakdown The perception of Catalyst Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Maintains Buy $26.00 $26.00 Andrew Fein HC Wainwright & Co. Raises Buy $26.00 $24.00 Leland Gershell Oppenheimer Maintains Outperform $29.00 $29.00 Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Samantha Semenkow Citigroup Announces Buy $27.00 - Jason Gerberry B of A Securities Announces Buy $23.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' ...Full story available on Benzinga.com

CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.